Related Experiment Video
Updated: Jan 2, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Developments in anticancer vaccination: budding new adjuvants
1Section of Biochemical Pharmacology, Medical University of Innsbruck, A-6020 Innsbruck, Austria.
Abstract:
The immune system has a limited capacity to recognize and fight cells that become cancerous and in cancer patients, the immune system has to seek the right balance between cancer rejection and host-immunosupression. The tumor milieu builds a protective shell and tumor cells rapidly accumulate mutations that promote antigen variability and immune-escape. Therapeutic vaccination of cancer is a promising strategy the success of which depends on a powerful activation of the cells of the adaptive immune system specific for tumor-cell detection and killing (e.g. CD4+ and CD8+ T-cells). In the last decades, the search for novel adjuvants that enhance dendritic cell (DC) function and their ability to prime T-cells has flourished and some Toll-like receptor (TLR) agonists have long been known to be valid immune adjuvants. The implementation of TLR-synthetic agonists in clinical studies of cancer vaccination is replacing the initial use of microbial-derived products with some encouraging results. The purpose of this review is to summarize the latest discoveries of TLR-synthetic agonists with adjuvant potential in anti-cancer vaccination.
Insights
Synthetic Toll-like receptor (TLR) agonists show promise as adjuvants in cancer vaccination. These compounds enhance dendritic cell function, boosting adaptive immune responses crucial for tumor cell detection and killing.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- The immune system's capacity to combat cancer is limited, requiring a balance between tumor rejection and immunosuppression.
- Tumor microenvironments create protective barriers, and cancer cells develop mutations for immune evasion.
- Effective cancer therapeutic vaccination necessitates robust activation of adaptive immune cells like CD4+ and CD8+ T-cells.
Purpose of the Study:
- To review recent advancements in synthetic Toll-like receptor (TLR) agonists.
- To explore the adjuvant potential of these TLR agonists in anti-cancer vaccination strategies.
Main Methods:
- Literature review focusing on synthetic TLR agonists.
- Analysis of their role in enhancing dendritic cell (DC) function.
- Evaluation of their impact on T-cell priming for anti-cancer immunity.
Main Results:
- Synthetic TLR agonists are emerging as effective immune adjuvants in cancer vaccination.
- They improve dendritic cell maturation and antigen presentation capabilities.
- Clinical studies show encouraging results with TLR agonists replacing traditional microbial adjuvants.
Conclusions:
- Synthetic TLR agonists represent a significant advancement in cancer vaccine adjuvant development.
- Their ability to potentiate anti-tumor adaptive immunity offers a promising therapeutic avenue.
- Further research and clinical application of TLR agonists are warranted for improved cancer treatment outcomes.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...